陳威君醫師
現職
新北市立土城醫院（委託長庚醫院經營）婦科腫瘤 助理教授級 主治醫師
林口長庚醫院 婦產部婦科腫瘤 助理教授級 主治醫師
桃園長庚醫院海扶刀中心專任醫師
台灣婦科海扶治療醫學會理事
專長
海扶刀治療子宮肌瘤及腺瘤免開刀無傷口手術
達文西機械手臂手術(肌瘤切除、腺瘤切除、子宮內膜癌婦癌淋巴分期微創手術）
子宮肌腺瘤微波消融手術
腹腔鏡微創手術(子宮肌瘤切除、肌腺瘤切除、子宮內膜異位症、巧克力囊腫、卵巢囊腫手術、沾黏分離手術)
子宮腔鏡手術、瘜肉手術
婦科腫瘤癌症(子宮頸癌、子宮內膜癌症、卵巢癌)手術、婦科癌症腹腔熱化學治療
子宮肌瘤/腺瘤保留子宮諮詢
陳威君醫師在婦科腫瘤領域具有以下特點：
【專業醫療和臨床經驗】
陳威君醫師專精婦科腫瘤和婦科癌症診治的專家，在醫療和學術領域具有豐富專業知識和技能，擅長各種婦科腫瘤手術和婦科癌症手術，包括微創手術和無創無痕的海扶刀治療子宮肌瘤和子宮肌腺症手術。此外，陳威君醫師也熟練運用達文西機械手臂進行手術，包括肌瘤切除、腺瘤切除以及子宮內膜癌和婦癌淋巴分期的微創手術。陳醫師在手術和臨床實踐上擁有豐富經驗，作為一名微無創手術專家，陳醫師以病人為中心，提供患者合適的治療計畫，以減少對病人的傷害並提升醫療品質。
【親切友善的醫病關係】
陳威君醫師以親力親為的態度與患者溝通，建立良好的醫病關係，以親切友善的方式對待患者，讓患者感受到溫暖和關懷，並且用心照顧女性朋友的健康，並積極回應患者的需求和疑慮。
【專業海扶醫療團隊合作】
1.陳威君醫師 自2018年開始執行海扶手術，海扶治療案例數接近400例，為長庚體系現今最早施術的醫師，也是目前林口長庚海扶刀手術指引建立醫師，同時也是國際微無創醫學會認證的海扶手術施術醫師及專業教學醫師，多次受邀在內視鏡醫學會，超音波醫學會及海扶婦科腫瘤醫學會演講。
2.陳威君醫師與專業的海扶醫療團隊緊密合作。陳醫師精準地在術前判斷腫瘤的良性或惡性，並針對子宮肌瘤和子宮腺肌症進行高強度聚焦超聲消融治療。同時，專業麻醉團隊隨時監控患者的反應，以確保手術過程達到舒適和安全的目標。
3.擔任桃園院區海扶刀治療中心專任醫師，負責建立桃園長庚海扶刀中心的操作規範和常規指引。同時，陳威君醫師也擔任台灣婦科海扶醫學會的理事。
4.在2021年，陳威君醫師參與了桃園院區海扶刀中心的防疫規劃，為患者的治療安全提供保障。
獲獎紀錄：
・榮獲2023年徐千田防癌研究基金會優秀論文獎第一名
・論文「Hyperthemic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer
・榮獲2022年徐千田防癌研究基金會優秀論文獎第二名
・論文「Prediction of myometrial invasion in stage I endometrial cancer by MRI: the influence of surgical diagnostic procedure」刊登在Cancers期刊上，獲得基隆長庚院區優秀論文
論文發表：
(1)Chen WC #, Qiu JT #, Huang HJ, Lin CT, Chen MY, Lai CH*, et al. Outcomes and prognoses of patients with ovarian cancer using bevacizumab: 6-year experience in a tertiary care hospital of northern Taiwan. https://doi.org/10.1371/journal.pone.0175703 (26/73=34.93%) (published online 3 May 2017; SCI impact factor: 3.240) (First author with equal contribution #)
(2)Chen WC, Huang HJ, Chang TC, Chou HH*. Dose-dense chemotherapy with weekly paclitaxel and 3-weekly carboplatin for recurrent ovarian cancer. Taiwan J Obstet Gynecol 2020;59(1):21-7. https://doi.org/10.1016/j.tjog.2019.10.003 (72/83=86.14%) (published online in Jan 2020; SCI impact factor: 1.705) (First author)
(3)Huang HJ, Tung HJ, Yang LY, Ku FC, Chao A, Tang YH, Chou HH, Chang WY, Wu RC, Huang CC, Chen WC, Lin CT, Huang KG, Wang CJ, Chang TC, Lai CH*. Role of human papillomavirus status after conization for high-grade cervical intraepithelial neoplasia. https://doi.org/10.1002/ijc.33251 (42/242=17.15%) (published online 1 Sep 2020; SCI impact factor: 7.396) (coauthor)
(4)Chou HH, Chen WC, Yan LY, Huang HJ, Chan WY, Lin H, Wu RC, Chen MY, Qiu JT, Huang KG, Chao A, Chang TC, Lai CH*. Postoperative adjuvant dose-dense chemotherapy with bevacizumab and maintenance bevacizumab after neoadjuvant chemotherapy for advanced ovarian cancer: A phase II AGOG/TGOG trial. Eur J Obstet Gynecol Reprod Biol. 2021 Apr 18;262:13-20. https://doi.org/10.1016/j.ejogrb.2021.04.017 (49/83=58.43%) (published on line 18 Apr 2021; SCI impact factor: 2.435) (Coauthor)
(5)Lin CY, Tsai CL, Chao A, Lee LY, Chen WC, Tang YH, Chao AS, Lai CH*. Nucleophosmin/B23 promotes endometrial cancer cell escape from macrophage phagocytosis by increasing CD24 expression. J Mol Med (Berl). 2021 May 5. https://doi.org/10.1007/s00109-021-02079-x (48/175=27.14%) (published on line 5 May 2021; SCI impact factor: 4.599) (Coauthor)
(6)Chang SH, Chang TC, Chen MY, Chen WC, Chou HH*. Comparison of the Efficacy and Safety of Dinalbuphine Sebacate, Patient-Controlled Analgesia, and Conventional Analgesia After Laparotomy for Gynecologic Cancers: A Retrospective Study. Journal of Pain Research. 2021 Jun 15; 2021:14:1763-1711. https://doi.org/10.2147/JPR.S314304 (114/208=54.57%) (published on line 15 Jun 2021; SCI impact factor: 3.133) (Coauthor)
(7)Chen WC, Hsu LT, Huang YT, Pan YB, Ueng SH, Chou HH*, Chang TC*. Prediction of myometrial invasion in stage 1 endometrial cancer by MRI: The influence of surgical diagnostic procedure. Cancers. 2021 Jun 30; 2021:13(13), 3275. https://doi.org/10.3390/cancers13133275 (51/242=20.87%) (published on line 30 Jun 2021; SCI impact factor: 6.639) (First author)
(8)Cheng WJ, Chiang CC, Peng MT, Huang YT, Huang JL, Chang SH, Yang HT, Chen WC, Kuo JJ, Hwang TL*. Chronic Obstructive Pulmonary Disease Increases the Risk of Mortality among Patients with Colorectal Cancer: A Nationwide Population-Based Retrospective Cohort Study. Int J Environ Res Public Health. 2021 Aug 19;18(16):8742. https://doi.org/10.3390/ijerph18168742. (42/176=23.86%)(published on line 19 Aug. 2021; SCI impact factor: 3.390) (Coauthor)
(9)Lin YP, Chen WC, Cheng CM, Shen CJ*. Vaginal pH Value for Clinical Diagnosis and Treatment of Common Vaginitis. Diagnostics 2021, 11(11), 1996. https://doi.org/10.3390/diagnostics11111996. (45/167=26.95%)(published on line 27 Oct. 2021; SCI impact factor: 3.706) (Coauthor)
(10)Chen WC, Huang HJ, Yang LY, Pan YB, Huang KG, Lin CT, Chen MY, Tang YH, Chang TC, Lai CH, Chou HH*. Hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer. Biomedical Journal 2021 Oct 14;S2319-4170(21)00137-2. https://doi.org/10.1016/j.bj.2021.10.003. (52/140=37.14%)(SCI impact factor: 4.910)(First author)
(11)Chen WC #, Chang TC, Chou HH*. Reply: Serum CA-125 and renal impairment in patients undergoing hyperthermic intraperitoneal chemotherapy. Biomedical Journal 2022 Jan 19;S2319-4170(22)00022-1. https://doi.org/10.1016/j.bj.2022.01.012. (52/140=37.14%)(SCI impact factor: 4.910)(Letter to editors)(First author)
(12)Chen WC #, Cheng CM, Liao WT, Chang TC*. Urinary Biomarkers for Detection of Clinical Endometriosis or Adenomyosis. Biomedicines 2022 Apr 1;10(4):833. DOI: https://doi.org/10.3390/biomedicines10040833. (33/276=11.95%) (published online in 1st April 2022; SCI impact factor: 6.081)(First author)
(13)Chen WC #, Ngan HY #, Yan LY #, Chang WY, Wu RC, Chen CY, Lin H, Cheng YM, Kan YY, Tseng CJ, Chang CC, Jung SM, Tung HJ, Tang YH, Lin CT, Chao A, Lai CH*. Verification of HPV16 as a good prognostic factor for cervical adeno-adenosquamous carcinoma via an international collaborative study. Taiwan J Obstet Gynecol 2022 May; 61(3):494-500. DOI: https://doi.org/10.1016/j.tjog.2022.03.036. (72/83=86.14%) (published online in May 2022; SCI impact factor: 1.705)(First author with equal contribution #)
受邀演講：
2021
・October 31,2021, 台灣婦科海扶治療醫學會 Letrozole of HIFU Treatment of myoma
・October 17, 2021, 中華民國醫用超音波學會 The HIFU Treatment of Leiomyoma and Adenomyosis 海扶刀：超音波治療婦科腫瘤
・August 26, 2021, 2021 APAGE-ISMIVS HIFU Webinars-Episode 2 Video Presentation | Dr. Wei-Chun Chen-HIFU Treatment for Adenomyosis & Myoma Uterine
2020
・September 26,2020, 台灣婦科海扶治療醫學會年會暨學術研討會,演講主題：長庚醫院治療經驗分享Application of Leuprolide in HIFU
2019
・October 26,「2019臺北腫瘤熱療國際研討會」講者Preliminary experience of hyperthermic intraperitoneal chemotherapy after debulking surgery for ovarian cancer
・October 10 – 12, 2019, The 6th Biennial Meeting of Asian Society of Gynecologic Oncology, 2019ASGO Acceptance Notice for Oral Presentation：Preliminary experience of hyperthermic intraperitoneal chemotherapy after debulking surgery for ovarian cancer
・July 21, 2019, 台灣中醫藥品質醫學會 經痛、不孕症與子宮肌腺症中西醫最新療法學術講座,演講主題：1.婦科腫瘤之超音波及核磁共振影像判讀2. 海扶刀技術原理與發展沿革與治療子宮腫瘤經驗分享
・April 28, 2019, 台灣婦科海扶治療醫學會年會暨學術研討會,演講主題：長庚醫院治療經驗分享HIFU in Linkou Chang Gung Memorial Hospital
2018
・April 28, 2018, 台灣精準醫學會：卵巢癌硏討會卵巢癌的化療(含 HIPEC 熱化療)
・March 17, 2018, 台灣婦產科醫學會年會暨擴大學術研討會論文發表：腹腔熱化療於卵巢癌的應用: 單一醫學中心的經驗Hyperthermic intraperitoneal chemotherapy in gynecologic cancer: the experience in one tertiary hospital of northern Taiwan
・February 23, 2018台灣婦癌醫學會Should patients go to ICU after HIPEC? Response and complications of HIPEC in recurrent ovarian cancer
2017
・August 29, 2017, 林口長庚醫院婦癌病友座談會手術中之高溫熱化學治療之介紹
・March 18, 2017, 台灣婦產科醫學會國際學術交流Intraperitoneal administration of Bevacizumab for management of malignant ascites of epithelial ovarian cancer: experience in a tertiary care hospital of northern Taiwan
・擔任林口長庚醫院護理部『專科護理師培育訓練』課程講師
・November 23, 2021, 擔任2021年度林口長庚醫院護理部『專科護理師培育訓練』課程講師 題目：婦女疾病之病生理、評估診斷與處置
・August 13, 2020, 擔任2020年度林口長庚醫院護理部『專科護理師培育訓練』課程講師題目：婦女疾病之病生理、評估診斷與處置
書籍雜誌採訪
・長庚醫訊41卷第9期，出刊日：2020年09月01日，主題：子宮肌瘤的無創治療
・嬰兒與母親雜誌採訪，出刊日：2018年08月07日，主題：這些癌症徵兆，可能與懷孕症狀混淆？真的嗎？
